ArticleEBioMedicine2026
Pre- and post-diagnosis signalling lipid profiles in heart failure with preserved ejection fraction: a prospective cohort study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is a prevalent syndrome with limited diagnostic and therapeutic options. Dyslipidaemia is a common comorbidity, and signalling lipids, bioactive molecules regulating key pathophysiological processes, are implicated in HFpEF, though their relationships remain unclear.
methodsPlasma samples from the PREVEND cohort were analysed, including 172 control samples, 125 PreDx-HFpEF samples (before diagnosis), and 30 PostDx-HFpEF samples (after diagnosis, paired with PreDx-HFpEF). A total of 261 signalling lipids were profiled via LC-MS/MS. Additionally, sums and ratios of specific signalling lipid targets were calculated. Cox proportional hazards and logistic regression models were performed to identify relationships between signalling lipids and HFpEF progression.
findingsPreDx-HFpEF individuals showed elevated non-esterified oxylipins (derived from DHA, AA, EPA) and specific lysophospholipids, compared with controls, and these signalling lipids emerged as potential predictors of incident HFpEF. In contrast, the PostDx-HFpEF subgroup demonstrated an attenuation of non-esterified oxylipins and lysophospholipids compared with control and PreDx-HFpEF samples, although findings are exploratory given the limited sample size. Among 103 detected non-esterified oxylipins, 44 showed significant associations with HFpEF-related outcomes. Together with 18 additional signalling lipids, this yielded 62 significant signalling lipids, 68% of which were independent of high-density lipoprotein (HDL).
interpretationSelected signalling lipids provide predictive information prior to HFpEF diagnosis, whereas post-diagnostic lipid alterations reflect disease-associated metabolic changes and should be interpreted cautiously. These findings highlight the potential relevance of signalling lipids in HFpEF.
fundingThis study was funded by Netherlands Heart Foundation, Chinese Scholarship Council, and Dutch Research Council.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.